Minot Light Capital: Rockwell Medical ($RMTI) Investment Case

In its Q2 2026 investor letter, Minot Light Capital Partners discusses Rockwell Medical (RMTI) as one of three portfolio holdings highlighted to illustrate the firm’s stock-picking process. Minot Light frames Rockwell as fitting a recurring pattern the firm has profited from previously with names like Outset Medical (OM) and MaxCyte (MXCT): a sub-$50 million market cap, sub-$25 million enterprise value company whose shares trade below $1.00 and that is forced into a reverse stock split to avoid delisting. The firm believes this combination of factors creates opportunities to buy fundamentally healthy businesses at or below net cash value, and views Rockwell as potentially more attractive than its prior examples because, in Minot Light’s assessment, the company should now be sustainably cash-flow positive, whereas OM and MXCT were still burning cash.

Business Overview
Minot Light describes Rockwell’s core business as centered on hemodialysis bicarbonate concentrates, a market the firm characterizes as an effective US duopoly with generally recurring revenue. The firm notes it has followed Rockwell since the fund’s inception and has had extensive conversations with management over that period.

Management and Turnaround Execution
The firm credits CEO Dr. Mark Strobeck, who joined in 2022, with guiding Rockwell through several challenging periods while steadily expanding margins, bringing the company to what Minot Light believes is now a positive cash flow position.

Building the Position Around the Reverse Split
Minot Light explains it built its position gradually in 2026 rather than all at once, citing two reasons: first, the firm’s experience that distressed micro-caps often don’t bottom until shares reach or fall below net cash per share; and second, its expectation that an anticipated reverse split announcement would trigger a predictable wave of arbitrary selling the firm wanted to capitalize on. That announcement came on June 29, 2026, with the split effective July 1, 2026, and the firm notes shares fell approximately 24% from a $6.80 high on 6/26 to a $5.19 low on 7/1 (post-split). Minot Light states it meaningfully increased its RMTI position during this window, viewing the sell-off as a classic inefficiency the firm has historically exploited around reverse-split announcements.

Valuation and Risk/Reward
The firm lays out a risk/reward framework based on Rockwell continuing to execute: revenue growing from a roughly $70 million run-rate to $100 million by 2030, generating $5-10 million in free cash flow. Against a ~$5.50 share price, 4.6 million fully diluted shares, and $15 million of net cash, Minot Light calculates a $25 million market cap, a $10 million enterprise value, and a 0.14x EV/Sales ratio, with net cash and investments of roughly $3.50 per share. Using the mid-range of $7.5 million in free cash flow against 5 million shares outstanding by 2030, the firm arrives at $1.50 of FCF per share, which at a 12x multiple would imply an $18.00 stock. In a bull case of $2.00 FCF per share at a 15x multiple, the firm sees $30.00 per share, with a “bigger bull case” premised on Rockwell entering what the firm calls a virtuous circle of lower cost of capital and accretive M&A that could push revenue well over $100 million and draw institutional interest.

Risks
Minot Light acknowledges the position has been a detractor for the fund, even as the firm added to it during the quarter. The firm states it does not believe shares will trade below the roughly $3.50 net cash floor and, with the reverse split now behind the company, projects downside of $3.50-$4.00 per share against upside to $30.00, versus the $5.50 share price referenced in the letter.

Minot Light Capital Partners views Rockwell Medical as a representative example of its broader approach to micro-cap investing: identifying companies with recurring revenue, capable management, and technical dislocations — in this case a reverse stock split — that the firm believes create a favorable asymmetry between limited downside near net cash value and substantial upside if the company’s cash-flow inflection and growth plan play out.

Click here for the full Pro Investor Letter.